Thomas Gajewski, MD, PhD, will receive this year's ESMO Award for Immuno-Oncology.
The award recognizes Gajewski’s work exploring why some patients are resistant to immunotherapy and how to restore the anti-cancer immune response.
Gajewski is AbbVie Foundation professor of cancer immunotherapy in the Ben May Department for Cancer Research, as well as professor of pathology and medicine at University of Chicago.
His research has explored the tumor microenvironment to help determine how it influences tumor responses to the immune system.
“The clinical benefit of checkpoint blockade immunotherapy will hit a plateau, so understanding mechanisms of resistance or failure of the current approaches is necessary to expand efficacy further,” Gajewski said in a press release. “Studying secondary mechanisms of resistance is already leading to new pathways and candidate targets.”
Gajewski will receive the award at this year’s ESMO Immuno-Oncology Congress, scheduled for Dec. 11-14 in Geneva.